📊 VGLS Key Takeaways
Is VG Life Sciences Inc. (VGLS) a Good Investment?
VG Life Sciences exhibits critical financial distress with zero revenue, negative stockholders' equity of -$4.3M, and only $22.9K in cash reserves. The company is technically insolvent with liquidity ratios near zero (0.01x), indicating inability to meet near-term obligations without immediate capital infusion. Continued losses of $3.9M net income and $361.7K capital expenditures are unsustainable.
Why Buy VG Life Sciences Inc. Stock? VGLS Key Strengths
- Pharmaceutical sector offers potential for breakthrough products if pipeline exists
- Modest asset base of $1.1M provides some liquidation value
- No significant long-term debt burden relative to equity
VGLS Stock Risks: VG Life Sciences Inc. Investment Risks
- Zero revenue generation - no commercial operations despite 10+ years in market
- Negative stockholders' equity indicates technical insolvency
- Critically low liquidity (0.01x current ratio) with only $22.9K cash
- Severe cash burn unsustainable without continuous external funding
- Financial data is 10+ years old (2015-09-30) - operational status unclear
- Zero insider activity in past 90 days suggests potential company abandonment
Key Metrics to Watch
- Revenue and sales - must demonstrate viable product commercialization
- Updated SEC filings - need current financial statements to assess ongoing viability
- Cash position and monthly burn rate - survival timeline without funding
- Path to positive stockholders' equity - structural insolvency must be addressed
VG Life Sciences Inc. (VGLS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
VGLS Profit Margin, ROE & Profitability Analysis
VGLS vs Healthcare Sector: How VG Life Sciences Inc. Compares
How VG Life Sciences Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is VG Life Sciences Inc. Stock Overvalued? VGLS Valuation Analysis 2026
Based on fundamental analysis, VG Life Sciences Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
VG Life Sciences Inc. Balance Sheet: VGLS Debt, Cash & Liquidity
VGLS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: VG Life Sciences Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline.
VGLS Revenue Growth, EPS Growth & YoY Performance
VGLS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2015 | N/A | -$1.0M | N/A |
| Q2 2015 | N/A | -$1.4M | N/A |
| Q1 2015 | N/A | -$1.5M | N/A |
| Q3 2014 | N/A | -$1.1M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
VG Life Sciences Inc. Dividends, Buybacks & Capital Allocation
VGLS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for VG Life Sciences Inc. (CIK: 0001091326)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VGLS
What is the AI rating for VGLS?
VG Life Sciences Inc. (VGLS) has an AI rating of STRONG SELL with 90% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VGLS's key strengths?
Claude: Pharmaceutical sector offers potential for breakthrough products if pipeline exists. Modest asset base of $1.1M provides some liquidation value.
What are the risks of investing in VGLS?
Claude: Zero revenue generation - no commercial operations despite 10+ years in market. Negative stockholders' equity indicates technical insolvency.
What is VGLS's revenue and growth?
VG Life Sciences Inc. reported revenue of $0.0.
Does VGLS pay dividends?
VG Life Sciences Inc. does not currently pay dividends.
Where can I find VGLS SEC filings?
Official SEC filings for VG Life Sciences Inc. (CIK: 0001091326) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VGLS's EPS?
VG Life Sciences Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VGLS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, VG Life Sciences Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VGLS stock overvalued or undervalued?
Valuation metrics for VGLS: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VGLS stock in 2026?
Our dual AI analysis gives VG Life Sciences Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VGLS's free cash flow?
VG Life Sciences Inc.'s operating cash flow is N/A, with capital expenditures of $361.7K.
How does VGLS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.01 (avg: 2).